The Huatai Securities Research Report said that on April 10, the US FDA announced that it will reduce, improve or replace animal testing requirements in the development of monoclonal antibody therapies and other drugs through a series of methods, including AI-based toxicity calculation models and cell line and organoid toxicity tests carried out in a laboratory environment. The plan is to launch a pilot project in 2025, allowing some pharmaceutical companies to completely skip animal testing under FDA supervision. The comprehensive policy update is expected to be completed in 2026. This FDA policy will further promote AI coverage in new drug development, accelerate from chemical synthesis to biological aspects such as pre-clinical and clinical trials, and push innovative pharmaceutical companies to increase investment in AI drug discovery platforms. It was once again emphasized that “AI+ Healthcare” will usher in leaps and bounds in 2025, and attention should be paid to related investment opportunities.

The Huatai Securities Research Report said that on April 10, the US FDA announced that it will reduce, improve or replace animal testing requirements in the development of monoclonal antibody therapies and other drugs through a series of methods, including AI-based toxicity calculation models and cell line and organoid toxicity tests carried out in a laboratory environment. The plan is to launch a pilot project in 2025, allowing some pharmaceutical companies to completely skip animal testing under FDA supervision. The comprehensive policy update is expected to be completed in 2026. This FDA policy will further promote AI coverage in new drug development, accelerate from chemical synthesis to biological aspects such as pre-clinical and clinical trials, and push innovative pharmaceutical companies to increase investment in AI drug discovery platforms. It was once again emphasized that “AI+ Healthcare” will usher in leaps and bounds in 2025, and attention should be paid to related investment opportunities.